Prior to joining Amgen, Dr. Sheridan practiced medicine at the Royal Melbourne Hospital in Victoria, Australia as Head of the Bone Marrow Transplant Service. He earned his MB BS degree (MD equivalent) at the University of Melbourne in Victoria. Dr. Sheridan is a board-certified fellow of the Royal Australasian College of Physicians (FRACP), with a sub-specialty in medical oncology.
"I am excited to join BioCryst, especially at a time when we are advancing our promising pipeline towards the market. The discovery unit at BioCryst has created novel therapeutics against important disease targets, across a range of therapeutic indications. I believe our product candidates have the potential to positively impact human health around the globe," stated Dr. Sheridan. "BioCryst has assembled a high-quality experienced leadership team, and it is a privilege to join this group."
BioCryst Pharmaceuticals, Inc. is a leader in the use of
crystallography and structure-based drug design for the development of
novel therapeutics to treat cancer, cardiovascular diseases, autoimmune
diseases and viral infections. The Company is advancing multiple internal
programs toward potential commercialization including forodesine HCl in
oncology, BCX-4208 in psoriasis and peramivir in seasonal and
life-threatening influenza. BioCryst is collaborating with Mundipharma for
the development and commercialization of forodesine HCl in markets across
Europe, Asia, Australia and certain neighboring countries. In January 2007,
the U.S. Department of Health and Human Services (HHS) awarded a $102.6
million, four-year contract to BioCryst to advance development of peramivir
to treat seasonal and life-threatening influenza. In February 2007,
BioCryst established a partnership with Shionogi & Co. to develop and
|SOURCE BioCryst Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved